KCNK9 and breast carcinoma: In vitro, Withaferin-A has been shown to reduce the proliferation of the human breast cancer cell line MDA-MB-231 by inhibiting the two-pore domain potassium (K2P9) channel TASK-3 (Zúñiga et al., 2020).